首页> 美国卫生研究院文献>Future Science OA >Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer

【2h】

Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer

机译：唑来膦酸治疗转移性去势抵抗性前列腺癌的男性抑制骨转换的持续时间

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aim:Zoledronate is approved for use every 3 weeks in men with bone metastases from castrate-resistant prostate cancer (CRPC) but the basis for such frequency is unclear.

机译：目的：唑来膦酸盐被批准每3周用于患有去势抵抗性前列腺癌（CRPC）骨转移的男性，但这种频率的依据尚不清楚。

著录项

期刊名称 Future Science OA
作者
Saroj Niraula; Arnoud J Templeton; Francisco Vera-Badillo; Anna Dodd; Zoann Nugent; Anthony M Joshua; Ian F Tannock;
展开▼
作者单位

展开▼
年(卷),期 2018(4),1
年度 2018
页码 FSO253
总页数 6
原文格式 PDF
正文语种
中图分类情报学;
关键词

相似文献

外文文献
中文文献
专利

1. Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer [J] . Saroj Niraula, Arnoud J Templeton, Francisco Vera-Badillo, Future Science OA . 2018,第1期

机译：唑来膦酸治疗转移性去势抵抗性前列腺癌的男性抑制骨转换的持续时间
2. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. [J] . Ryan CW, Huo D, Bylow K, BJU international . 2007,第1期

机译：激素敏感性前列腺癌并接受唑来膦酸治疗的患者骨密度下降和骨转换的抑制。
3. Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: A possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw? [J] . RistowO., Gerngro?C., SchwaigerM., Journal of Cancer Research and Clinical Oncology . 2014,第3期

机译：定期的唑来膦酸会改变患有转移性前列腺癌的男性颌骨的骨转换吗？这可能是双膦酸酯相关性颌骨坏死的发病机制的线索？
4. Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer: A Decade of Progress and Ongoing Discoveries [C] . Leonel Hernez-Aya, Maha Hussain Genitourinary Cancers Symposium. . 2014

机译：转移激素敏感和阉割的前列腺癌：进步和持续发现的十年
5. Muscle Cross-Sectional Area Is Improved and Physical Funciton Is Maintained After Home-Based Exercise in Men with Metastatic Castration-Resistant Prostate Cancer Undergoing Androgen Deprivation Therapy [D] . Alzer, Mohamdod Saber. 2020

机译：改善肌横截面积，并且在具有转移阉割的前列腺癌接受雄激素剥夺治疗的男性中的男性锻炼之后，将物理静脉凝集维持
6. Usefulness of bone turnover markers as predictors of mortality risk disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study [O] . C de la Piedra, A Alcaraz, J Bellmunt, 2013

机译：唑来膦酸治疗后骨转移的前列腺癌患者的骨转换指标可作为预测死亡风险疾病进展和骨骼相关事件的指标：TUGAMO研究
7. Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer [O] . Saroj Niraula, Arnoud J Templeton, Francisco Vera-Badillo, 2018

机译：用转移性阉割的前列腺癌治疗唑代酸治疗后骨移植抑制持续时间
8. Glyphosate Vedotin for Treatment of Bone Metastatic Castration-Resistant Prostate Cancer. [R] . You, Z. 2015

机译：草甘膦Vedotin治疗骨转移性去势抵抗前列腺癌。

Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer

摘要

著录项

相似文献

相关主题

期刊订阅